Myelodysplasia
ML Heaney, DW Golde - New England Journal of Medicine, 1999 - Mass Medical Soc
The myelodysplastic syndromes are clonal hematologic disorders characterized clinically
and morphologically by ineffective hematopoiesis. The natural history of these syndromes …
and morphologically by ineffective hematopoiesis. The natural history of these syndromes …
Myelodysplastic syndromes
PL Greenberg, NS Young… - ASH Education Program …, 2002 - ashpublications.org
The myelodysplastic syndromes (MDS) are characterized by hemopoietic insufficiency
associated with cytopenias leading to serious morbidity plus the additional risk of leukemic …
associated with cytopenias leading to serious morbidity plus the additional risk of leukemic …
Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology
PL Greenberg, RM Stone, A Al-Kali, SK Barta… - Journal of the National …, 2017 - jnccn.org
The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated …
CS Cutler, SJ Lee, P Greenberg, HJ Deeg, WS Pérez… - Blood, 2004 - ashpublications.org
Bone marrow transplantation (BMT) can cure myelodysplastic syndrome (MDS), although
transplantation carries significant risks of morbidity and mortality. Because the optimal timing …
transplantation carries significant risks of morbidity and mortality. Because the optimal timing …
Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after …
DA Wells, M Benesch, MR Loken, C Vallejo, D Myerson… - Blood, 2003 - ashpublications.org
Marrow cells of myeloid lineage from 115 patients with myelodysplastic syndrome (MDS)
were characterized by multidimensional flow cytometry and compared with findings in 104 …
were characterized by multidimensional flow cytometry and compared with findings in 104 …
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R
MG Della Porta, EP Alessandrino… - Blood, The Journal …, 2014 - ashpublications.org
Approximately one-third of patients with myelodysplastic syndrome (MDS) receiving
allogeneic hematopoietic stem cell transplantation (HSCT) are cured by this treatment …
allogeneic hematopoietic stem cell transplantation (HSCT) are cured by this treatment …
Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes.
D Bowen, D Culligan, S Jowitt… - British journal of …, 2003 - search.ebscohost.com
Presents guidelines for the diagnosis and therapy of adult myelodysplastic syndromes.
Pathophysiology; Diagnosis; Questions and answers regarding the diagnosis of MDS; …
Pathophysiology; Diagnosis; Questions and answers regarding the diagnosis of MDS; …
Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia
J Sierra, WS Pérez, C Rozman… - Blood, The Journal …, 2002 - ashpublications.org
Allogeneic hematopoietic stem cell transplantation is the only curative therapy for
myelodysplasia (MDS). To identify factors influencing transplantation outcome, we studied …
myelodysplasia (MDS). To identify factors influencing transplantation outcome, we studied …
Myelodysplastic syndromes
PL Greenberg, E Attar, JM Bennett… - Journal of the National …, 2011 - jnccn.org
Overview T he myelodysplastic syndromes (MDS) represent myeloid clonal hemopathies
with relatively heterogeneous spectrums of presentation. The major clinical problems in …
with relatively heterogeneous spectrums of presentation. The major clinical problems in …
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with …
HJ Deeg, B Storer, JT Slattery… - Blood, The Journal …, 2002 - ashpublications.org
A total of 109 patients (aged 6-66 years; median, 46 years) with myelodysplastic syndrome
(MDS) were treated with busulfan (BU) targeted to plasma concentrations of 800 to 900 …
(MDS) were treated with busulfan (BU) targeted to plasma concentrations of 800 to 900 …